These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36287217)

  • 61. Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis.
    Hong N; Shin S; Lee S; Rhee Y
    Osteoporos Int; 2023 Dec; 34(12):2059-2067. PubMed ID: 37596432
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study.
    Ishida T; Yoshida S; Fujiki Y; Hata K; Kotani T; Takeuchi T
    Arch Osteoporos; 2021 Feb; 16(1):39. PubMed ID: 33624165
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
    Leder BZ; Tsai JN; Neer RM; Uihlein AV; Wallace PM; Burnett-Bowie SA
    J Clin Densitom; 2016; 19(3):346-51. PubMed ID: 26900146
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
    Lewiecki EM; Blicharski T; Goemaere S; Lippuner K; Meisner PD; Miller PD; Miyauchi A; Maddox J; Chen L; Horlait S
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3183-3193. PubMed ID: 29931216
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
    Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study.
    Adami G; Pedrollo E; Rossini M; Fassio A; Braga V; Pasetto E; Pollastri F; Benini C; Viapiana O; Gatti D
    JBMR Plus; 2024 Apr; 8(4):ziae016. PubMed ID: 38544922
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
    Cosman F; Crittenden DB; Adachi JD; Binkley N; Czerwinski E; Ferrari S; Hofbauer LC; Lau E; Lewiecki EM; Miyauchi A; Zerbini CA; Milmont CE; Chen L; Maddox J; Meisner PD; Libanati C; Grauer A
    N Engl J Med; 2016 Oct; 375(16):1532-1543. PubMed ID: 27641143
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation.
    Makras P; Appelman-Dijkstra NM; Papapoulos SE; van Wissen S; Winter EM; Polyzos SA; Yavropoulou MP; Anastasilakis AD
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e4155-e4162. PubMed ID: 33978745
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis.
    Popp AW; Varathan N; Buffat H; Senn C; Perrelet R; Lippuner K
    Calcif Tissue Int; 2018 Jul; 103(1):50-54. PubMed ID: 29380013
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
    Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
    Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study.
    Matsumoto T; Sone T; Soen S; Tanaka S; Yamashita A; Inoue T
    J Clin Endocrinol Metab; 2022 Sep; 107(10):e4222-e4231. PubMed ID: 35977548
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
    Langdahl BL; Teglbjærg CS; Ho PR; Chapurlat R; Czerwinski E; Kendler DL; Reginster JY; Kivitz A; Lewiecki EM; Miller PD; Bolognese MA; McClung MR; Bone HG; Ljunggren Ö; Abrahamsen B; Gruntmanis U; Yang YC; Wagman RB; Mirza F; Siddhanti S; Orwoll E
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1335-42. PubMed ID: 25607608
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis.
    Okubo N; Matsui S; Matsumoto T; Sugimoto T; Hosoi T; Osakabe T; Watanabe K; Takami H; Shiraki M; Nakamura T
    Calcif Tissue Int; 2020 Dec; 107(6):559-566. PubMed ID: 32839843
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.
    Ishiguro S; Ito K; Nakagawa S; Hataji O; Sudo A
    Arch Osteoporos; 2017 Dec; 12(1):44. PubMed ID: 28425086
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism.
    Eller-Vainicher C; Palmieri S; Cairoli E; Goggi G; Scillitani A; Arosio M; Falchetti A; Chiodini I
    J Am Geriatr Soc; 2018 Mar; 66(3):518-524. PubMed ID: 29364518
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis.
    Yang L; Kang N; Yang JC; Su QJ; Liu YZ; Guan L; Liu T; Meng XL; Wang Y; Hai Y
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2640-2668. PubMed ID: 30964193
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
    Sumida K; Ubara Y; Hoshino J; Mise K; Hayami N; Suwabe T; Kawada M; Imafuku A; Hiramatsu R; Hasegawa E; Yamanouchi M; Sawa N; Takaichi K
    Osteoporos Int; 2016 Apr; 27(4):1441-1450. PubMed ID: 26525045
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.
    Mandema JW; Zheng J; Libanati C; Perez Ruixo JJ
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3746-55. PubMed ID: 24915115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.